Navigation Links
Aratana Therapeutics Announces Full Exercise of Over-Allotment Option

KANSAS CITY, Kan. and BOSTON, July 11, 2013 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative prescription medications for pets, today announced the full exercise of the over-allotment option granted to the underwriters to purchase 862,500 additional shares of common stock, at a public offering price of $6.00 per share, in connection with its previously announced initial public offering of 5,750,000 shares of common stock that closed on July 2, 2013, bringing the total gross proceeds from the offering to $39,675,000, before deducting the underwriting discounts and commissions and other offering expenses payable by Aratana Therapeutics.  The company's common stock is listed on The NASDAQ Global Market under the trading symbol "PETX."

Stifel and Lazard Capital Markets acted as lead book-running managers for the offering.  William Blair, JMP Securities and Craig-Hallum Capital Group acted as co-managers.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on June 26, 2013.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful.

The offering is being made only by means of a written prospectus forming part of the effective registration statement.  Copies of the prospectus related to the offering may be obtained from Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2720; or from Lazard Capital Markets LLC, Attn: Syndicate Department, 30 Rockefeller Plaza, 48th Floor, New York, NY 10020, or by calling (800) 542-0970.

Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D./Andrew Mielach; (212) 375-2664; (212) 375-2694

SOURCE Aratana Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Aratana Therapeutics Completes $15 Million Series B Financing
2. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
3. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
4. Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
5. Aratana Therapeutics Adds To Drug Development Team
6. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
7. Nile Therapeutics Reports 2011 Third Quarter Financial Results
8. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
9. Fate Therapeutics Strengthens Its iPSC Platform
10. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
11. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
Post Your Comments:
(Date:11/26/2015)... England , November 26, 2015 ... innovative medical device company specializing in imaging technologies, announced today ... European Commission as part of the Horizon 2020 European Union ... carry out a large-scale clinical trial in breast cancer. ... (Logo: , --> --> ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. 25, ... HART ), a biotechnology company developing bioengineered organ ... Jim McGorry will present at the LD Micro ... at 2:30 p.m. PT. The presentation will be webcast ... days. Management will also be available at the conference ...
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015  Rubicon Genomics, Inc., today announced ... of its DNA library preparation products, including the ... ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized ... NGS libraries for liquid biopsies--the analysis of cell-free ... applications in cancer and other conditions. Eurofins Scientific ...
(Date:10/29/2015)... OXFORD, Connecticut , October 29, 2015 /PRNewswire/ ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet announces that StackCommerce, a leading ... will be featuring the Wocket® smart wallet on ... NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:10/27/2015)... 27, 2015 In the present market scenario, ... for various industry verticals such as banking, healthcare, defense, ... growing demand for secure & simplified access control and ... as hacking of bank accounts, misuse of users, , ... as PC,s, laptops, and smartphones are expected to provide ...
Breaking Biology News(10 mins):